Clinical trial
A Multicenter, Global Confirmatory Study Evaluating the Efficacy and Safety of Quantum-Inspired Intervention (QII), a Novel Neurodevelopmental Intervention, for Improving Emotional Stability and Social Communication in Children With Autism Spectrum Disorder
NCT07898787 is registered in ClinicalTrials.gov with BlissBot, Inc as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started February 2027. Interventional study, 80 participants (estimated). Lead sponsor BlissBot, Inc. Primary measure: Clinical Global Impression-Improvement (CGI-I) Score for the Primary Intervention Target.
How it compares
547 similar trials: same condition (Autistic Disorder) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Global Confirmatory Study Evaluating the Efficacy and Safety of Quantum-Inspired Intervention (QII), a Novel Neurodevelopmental Intervention, for Improving Emotional Stability and Social Communication in Children With Autism Spectrum Disorder
- Lead sponsor
- BlissBot, Inc
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- February 28, 2027
- Completion date
- May 31, 2028
- Enrollment
- 80 (estimated)
- Sites
- Not reported
Conditions
MeSH condition names; the registry's own terms follow.
Autism Spectrum Disorder, Autistic Disorder
Registry terms: asd, autism spectrum disorder (asd
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 5 Years
- Maximum age
- 17 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Lead sponsor
- BlissBot, Inc
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Quantum-Inspired Intervention (QII) | Experimental | Quantum-Inspired Intervention (QII) |
Show registry wordingParticipants receive the proprietary Quantum-Inspired Intervention (QII) protocol over a 3-month intervention period. Delivery is conducted entirely remotely by trained practitioners without requiring on-site visits or added labor burden for the family. Following caregiver intake, AI-enabled developmental profiling, and caregiver-confirmed Developmental Report alignment, standardized non-contact protocol sessions are administered. Participants continue their usual care throughout the study. Efficacy endpoints are assessed by blinded independent assessors at baseline and at the end of the 3-month intervention period. | ||
| Waitlist Control (Delayed QII) | No intervention | |
Show registry wordingParticipants complete the identical procedural workflow as the experimental arm, including caregiver intake, AI-enabled developmental profiling, and Developmental Report alignment, and continue their usual care, but do not receive the QII protocol during the 3-month intervention period. Efficacy endpoints are assessed by blinded independent assessors at the same time points. Following completion of the primary analysis, participants are offered the QII protocol, provided that no safety concerns have been identified by the Data Monitoring Committee (DMC). | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Clinical Global Impression-Improvement (CGI-I) Score for the Primary Intervention Target | End of the 3-month QII intervention period |
Show registry wordingCGI-I rated by a blinded independent clinician on a 7-point scale (1 = very much improved; 7 = very much worse), assessing improvement relative to baseline in the autism-related symptom or functional difficulty identified as the primary intervention target at baseline. Response is defined as a CGI-I score of 1 (very much improved) or 2 (much improved). | |
Similar trials
Same condition (Autistic Disorder) and phase, most recent start first.
+542 more trials See the condition page